Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(incorporated in the Cayman Islands with limited liability) (Stock Code: 2038)

GRANT OF SUBSIDIARY'S SHARE OPTIONS

This announcement is made by FIH Mobile Limited (the "Company") pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

The Company hereby announces that on the date of this announcement, Bharat FIH Limited (formerly known as Rising Stars Mobile India Private Limited), an indirect subsidiary of the Company ("BFIH", and together with its subsidiary(ies), the "Subsidiary Group") granted a total of 93,110,000 share options (the "Options") to the executive directors of the Company (the "Director(s)") and certain eligible employees and third party service providers of the Subsidiary Group (collectively, the "Grantees") to subscribe for a total of 93,110,000 ordinary shares of Indian Rupees ("INR") 10.00 each in the share capital of BFIH (the "Subsidiary Shares"), subject to acceptance of the Grantees, under the share option scheme of BFIH approved and adopted by the Company's shareholders on 28 May 2021 (the "Subsidiary Scheme"). Details of the Options granted are as follows:

Date of grant : 23 December 2021 (the "**Date of Grant**")

Exercise price of Options granted : INR20.00 per Subsidiary Share as determined

by the board of directors of BFIH (after having taken into account, among other things, the nominal value and market value of a Subsidiary Share) in accordance with the Subsidiary

Scheme

Total number of Options granted : 93,110,000 Options (each Option shall entitle

the holder thereof to subscribe for one

Subsidiary Share)

Market price of a Subsidiary Share

on the Date of Grant

: Not applicable as the Subsidiary Shares are not securities that are listed on any exchange or other securities market in Hong Kong or

overseas

Validity period of the Options

The validity period of the Options shall commence from the vesting date of Option Grant and end within 5 years post vesting of the Options, subject to any early lapse thereof in accordance with the Subsidiary Scheme.

Exercise period of the Options

- : The Options granted shall be exercisable during the following periods (subject to the fulfillment of certain vesting conditions, if applicable):
 - (a) the first tranche (representing 30% of the Options) shall be exercisable from 23 December 2022 to 30 November 2027 (both dates inclusive);
 - (b) the second tranche (representing 30% of the Options) shall be exercisable from 1 December 2023 to 30 November 2028 (both dates inclusive); and
 - (c) the third tranche (representing 40% of the Options) shall be exercisable from 1 December 2024 to 30 November 2029 (both dates inclusive).

Among the Options granted, 24,000,000 Options were granted to the Directors, details of which are as follows:

Name of Director	Position held in the Company	Number of the Options Granted
CHIH Yu Yang	Executive Director and Chief Executive Officer	12,500,000
MENG Hsiao-Yi	Executive Director and Chief Operating Officer	11,000,000
KUO Wen-Yi	Executive Director	500,000

The grant of the above Options to each of the above Directors has been approved by the independent non-executive directors of the Company in compliance with Rule 17.04(1) of the Listing Rules.

Save as disclosed above, as at the date of this announcement, none of the Grantees is a director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company, or an associate (as defined in the Listing Rules) of any of them.

By Order of the Board **CHIH Yu Yang** *Acting Chairman*

Hong Kong, 23 December 2021

As at the date of this announcement, the board of directors of the Company comprises three executive directors, namely Mr. CHIH Yu Yang, Dr. KUO Wen-Yi and Mr. MENG Hsiao-Yi; and three independent non-executive directors, namely Mr. LAU Siu Ki, Dr. Daniel Joseph MEHAN and Mr. TAO Yun Chih.